Potential targets for pancreatic cancer immunotherapeutics.
Potential targets for pancreatic cancer immunotherapeutics.
复制标题
DOI：
10.2217/imt.11.10
复制
发表时间：
2011-04
期刊：
影响因子：
2.8
通讯作者：
Goedegebuure P
中科院分区：
文献类型：
--
作者：
Dodson LF;Hawkins WG;Goedegebuure P
胰腺癌是癌症死亡的第四大原因，总体5年生存率低于5%。由于有充分的证据表明胰腺癌引起抗肿瘤免疫应答，胰腺癌相关抗原的鉴定刺激了基于疫苗接种的治疗策略的发展。虽然在动物肿瘤模型中观察到了有希望的结果，但大多数临床研究只发现了有限的成功。由于大多数试验是在晚期胰腺癌患者中进行的，因此应考虑免疫抑制机制的作用。在这篇文章中，我们详细介绍了最近的工作，在肿瘤抗原疫苗接种和最近确定的免疫抑制胰腺癌的机制。我们就如何提高胰腺癌疫苗的临床疗效提供了我们的观点。
Pancreatic adenocarcinoma is the fourth leading cause of cancer death with an overall 5-year survival of less than 5%. As there is ample evidence that pancreatic adenocarcinomas elicit antitumor immune responses, identification of pancreatic cancer-associated antigens has spurred the development of vaccination-based strategies for treatment. While promising results have been observed in animal tumor models, most clinical studies have found only limited success. As most trials were performed in patients with advanced pancreatic cancer, the contribution of immune suppressor mechanisms should be taken into account. In this article, we detail recent work in tumor antigen vaccination and the recently identified mechanisms of immune suppression in pancreatic cancer. We offer our perspective on how to increase the clinical efficacy of vaccines for pancreatic cancer.